Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities

Du, Xiaohong; Zuo, Xiangyang; Fang, Meng; Wu, Fei; Zhao, Xin; Li, Chunfeng; Cheng, Genhong; Qin, F. Xiao-Feng

doi:10.1016/j.bbrc.2019.11.065

Cited by 44 publications

(34 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prophylactic administration of IFNs may block viral infection; daily IFNα nasal drops protected healthcare workers from COVID-19 over 28 days without noticeable side effects (NCT04320238). Azithromycin has shown antiviral activity both in vitro and in vivo on an array of viral strains including respiratory syncytial virus, Ebola, Zika, influenza H1N1 virus, enterovirus, and rhinovirus ( Table 2 ) [ [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] ]. Moreover, it can substantially reduce respiratory morbidity in infants with respiratory syncytial virus bronchiolitis [ 65 ].…”

Section: Spatiotemporal Modulation Of Host Antiviral Responsesmentioning

confidence: 99%

Azithromycin: The First Broad-spectrum Therapeutic

Firth

Prathapan

2020

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

The Strategic Plan for Biodefense Research by the U.S. Department of Health and Human Services demarcates the need for drugs which target multiple types of pathogens to prepare for infectious threats. Azithromycin is one such broad-spectrum therapeutic that is both included in the University of Oxford’s RECOVERY and excluded from the World Health Organization’s SOLIDARITY trials. Here we review azithromycin’s broad antibiotic, antimalarial, antiviral pharmacology and contextualise it against a broader history as the most repositioned therapeutic of the macrolide class; we further evaluate azithromycin’s clinical and socio-economic propriety for respiratory pandemics and delineate a model for its combinatorial mechanism of action against COVID-19 pneumonia.

show abstract

Section: Spatiotemporal Modulation Of Host Antiviral Responsesmentioning

confidence: 99%

Azithromycin: The First Broad-spectrum Therapeutic

Firth

Prathapan

2020

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…It has been shown that AZM has significant antiviral properties. In contrast with CQ or HCQ, its antiviral activity has been shown in vitro and/or in vivo on a large panel of viruses: Ebola, Zika, respiratory syncytial virus, influenzae H1N1 virus, enterovirus, and rhinovirus [4][5][6][7][8][9][10][11][12][13]. Its activity against respiratory syncytial virus has been demonstrated in a randomized study in infants [10].…”

mentioning

confidence: 99%

Azithromycin for COVID-19: More Than Just an Antimicrobial?

et al. 2020

View full text Add to dashboard Cite

“… 71 Du X et al., by combinatorial screening using pseudo-virion and mini-genome replicon systems, identified several drugs with some activity against Ebola virus and, among them, there was AZI. 72 While it is not yet known whether the macrolide antibiotic has a direct antiviral inhibitory effect, it might be speculated that some antiviral effect may be due its ability to amplify systemic antiviral response mediated by the IFN pathway. 73 …”

Section: Macrolides In Viral Diseasesmentioning

confidence: 99%

Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond

Poddighe

Aljofan

2020

Antivir Chem Chemother

View full text Add to dashboard Cite

Macrolides are a large group of antibiotics characterised by the presence of a macro-lactone ring of variable size. The prototype of macrolide antibiotics, erythromycin was first produced by Streptomyces and associated species more than half a century ago; other related drugs were developed. These drugs have been shown to have several pharmacological properties: in addition to their antibiotic activity, they possess some anti-inflammatory properties and have been also considered against non-bacterial infections. In this review, we analysed the available clinical evidences regarding the potential anti-viral activity of macrolides, by focusing on erythromycin, clarithromycin and azithromycin. Overall, there is no significant evidences so far that macrolides might have a direct benefit on most of viral infections considered in this review (RSV, Influenza, coronaviruses, Ebola and Zika viruses). However, their clinical benefit cannot be ruled out without further and focused clinical studies. Macrolides may improve the clinical course of viral respiratory infections somehow, at least through indirect mechanisms relying on some and variable anti-inflammatory and/or immunomodulatory effects, in addition to their well-known antibacterial activity.

show abstract

Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities

Cited by 44 publications

References 31 publications

Azithromycin: The First Broad-spectrum Therapeutic

Azithromycin: The First Broad-spectrum Therapeutic

Azithromycin for COVID-19: More Than Just an Antimicrobial?

Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond

Contact Info

Product

Resources

About